MAHA Summit corporate dominance; Trump Medicare drug price effort diluted

The MAHA Summit, a health policy event, is now dominated by corporate health care interests, signaling a shift from its original grassroots orientation. Concurrently, the Trump administration's initiative to lower Medicare drug prices has been weakened, reducing expected savings. This suggests policy momentum toward industry-friendly positions, with implications for pharmaceutical pricing and public health costs.